
Danish pharmaceutical giant Novo Nordisk is well on the way to achieving its 2025 goal for sales of weight loss drugs three years early. There is therefore a good chance that a new target will be revealed at the company’s upcoming capital markets day, on March 3.
”The goal will be within touching distance well before the 2025 deadline,” says CEO Lars Fruergaard Jørgensen to MarketWire, adding:
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app